Mounjaro Kwikpen 2.5MG/0.6ML 2.4ML - Weightloss Skinny Pens

Mounjaro (tirzepatide) is a weight loss treatment that comes in the form of a weekly self-injectable pen. Mounjaro should start working straight away, but it could take several weeks until it has a noticeable effect on regulating your blood sugar level and impacting your appetite and eating habits. The active ingredient in Mounjaro is called tirzepatide. Tirzepatide works on two different hormonal receptors: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). You may have heard of GLP-1 from other weight loss injections. GLP-1 helps to regulate blood sugar levels, which in turn talks to the brain to make you feel less hungry and prevent cravings. It also slows down the emptying of the stomach to keep you feeling fuller for longer. GIP regulates energy balance in brain and fat cells, enhancing the GLP-1 effect of suppressing your appetite and improving sugar control. By mimicking the effects of both these naturally occurring hormones, Mounjaro has been shown to have greater weight loss potential than medicines that work on GLP-1 alone. You inject Mounjaro under the skin (subcutaneously) in your stomach area, thigh or upper arm once a week using an injection pen. Don’t worry, it’s actually much easier than it sounds and if we prescribe Mounjaro for you, we’ll provide you with full instructions on how to use it. You must follow a strict dosage increase schedule as advised by your healthcare provider. To allow your body to get used to the medicine and have the best chance for long-term success, you should follow the gently increasing dosage schedule as instructed. Usually, you’ll start with a dose of 2.5 mg of Mounjaro, which will increase every four weeks (or as advised and if suitable for you) until you reach your maximum maintenance dose of 5mg, 10mg or 15mg. If you’re using Saxenda or Wegovy, you’ll need to wait 1 month before switching to Mounjaro. This is called the 'washout' period, and gives the body time for the first drug to leave the system. All patients using Mounjaro for the first time will start with 2.5mg. Keep in mind, Mounjaro may not be suitable for you (even if you're using another weight loss medicine). We’ll assess if it’s right for you during your consultation. Wegovy and Mounjaro are both weekly injection pens and work in similar ways to aid weight loss. Mounjaro has proven more effective in clinical trials, as it works on GLP-1 and GIP hormones, whereas Wegovy only works on GLP-1. However, Mounjaro is a new medicine in the UK so we don’t have as much safety data on it compared to other medicines in the long term. Deciding if or which medicine is right for you will depend on different factors, which we’ll assess during your consultation. If you’re already on Wegovy (or Saxenda) and losing weight, we recommend you keep using it. Keep in mind, weight plateaus are normal on your weight loss journey. Mounjaro (tirzepatide) 5mg injection, is a prescription medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose). It is not known if Mounjaro can be used in people who have had pancreatitis. Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age. It is a single molecule designed to bind to glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. Mounjaro represents a different class of medicines introduced for adults with type 2 diabetes. It works differently by directly activating GIP and GLP-1 pathways to help regulate blood sugar. Mounjaro (tirzepatide) 2.5 mg injection, is a prescription medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose). It is not known if Mounjaro can be used in people who have had pancreatitis. Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age. It is a single molecule designed to bind to glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. Mounjaro represents a different class of medicines introduced for adults with type 2 diabetes. It works differently by directly activating GIP and GLP-1 pathways to help regulate blood sugar.
Less